Results 1-6 of 6
Clifford Chance conseille Clayton, Dubilier & Rice pour son entrée en négociations exclusives avec les actionnaires de BUT, pour l'acquisition du groupe de magasins d'ameublement
1 July 2016
Clifford Chance a conseillé le fonds d'investissement Clayton, Dubilier & Rice (CD&R) dans le cadre de son entrée en négociations exclusives avec les actionnaires de BUT pour l'acquisition, aux cotés de WM Holding, véhicule d'investissement du groupe de meubles...
23 September 2015
International law firm Clifford Chance has advised Cinven, a leading European private equity firm, on the sale of Guardian Financial Services ('Guardian'), a UK life insurance consolidation business, to Admin Reinsurance ('Admin Re') with an enterprise value of...
Clifford Chance cross-practice team advises Salamander Energy plc on successful securities exchange offer from Ophir Energy plc
3 March 2015
A cross-practice team from leading international law firm Clifford Chance has advised Salamander Energy plc on its recommended share exchange acquisition by Ophir Energy plc, which became effective today. The successful completion of Ophir's recommended offer...
Clifford Chance advises Deutsche Telekom on the sale, together with Orange, of mobile operator EE to BT for £12.5 billion in cash and shares
9 February 2015
Clifford Chance has advised Deutsche Telekom AG which, along with Orange S.A, has reached an agreement with the British telecommunications operator BT Group plc. on the sale of their UK joint venture EE.
24 November 2014
International law firm Clifford Chance has advised Salamander Energy plc, a South East Asia-focused independent oil and gas exploration and production company listed on the main market of the London Stock Exchange, on its recommended offer from Ophir Energy plc....
15 October 2012
Leading international law firm Clifford Chance has advised CCM Pharma Midco Limited, a vehicle formed by Cinven Funds, on its purchase of Amdipharm. The transaction values Amdipharm at £365m. Amdipharm is a family-owned international niche pharmaceuticals business...